<DOC>
	<DOC>NCT01911676</DOC>
	<brief_summary>This study involves an interlinked design to determine the dose associated with optimal activity and occupancy of the Glyt1I PF-03463275 in healthy subjects and schizophrenia subjects and to test this dose in combination with cognitive remediation in the treatment of cognitive impairments of Schizophrenia.</brief_summary>
	<brief_title>Translational Neuroscience Optimization of GlyT1 Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1) Males or females 21 to 55 years of age (inclusive). 3) Able to provide written informed consent. 4) Only CYP2D6 extensive metabolizers. 1) No ongoing acute medical issues 2) Clinically significant ECG abnormality 3) Blood donation within eight weeks of the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>